Adjuvant and neoadjuvant chemotherapy in osteosarcoma

Area of Science:

• Oncology
• Orthopaedic Surgery
• Medical Oncology

Background:

• Associated chemotherapy, including adjuvant or neoadjuvant therapy, is vital for treating localized tumors with a high risk of micrometastasis.
• Osteosarcoma (OS) treatment commonly involves chemotherapy, but efficacy varies by OS subtype.
• This review focuses on primary high-grade OS of the limbs, a subset representing approximately 60% of all OS cases.

Purpose of the Study:

• To evaluate the effectiveness of different neoadjuvant chemotherapy protocols in treating localized, high-grade osteosarcoma of the limbs.
• To analyze treatment outcomes based on data from a large patient cohort treated at the Rizzoli Orthopaedic Institute.

Main Methods:

• Retrospective analysis of 731 patients diagnosed with primary high-grade OS of the limbs between 1983 and 1996.
• Patients received neoadjuvant chemotherapy administered via five distinct protocols.
• Focus on cases that were localized at diagnosis, excluding low-grade and metastatic forms.

Main Results:

• The study analyzed outcomes from five different neoadjuvant chemotherapy protocols.
• Data from 731 patients treated at the Rizzoli Orthopaedic Institute between 1983 and 1996 were included.
• Specific results comparing the five protocols are detailed in Table I (not provided in the abstract).

Conclusions:

• Neoadjuvant chemotherapy is a cornerstone in managing localized high-grade osteosarcoma of the limbs.
• The study provides valuable insights into the historical application and outcomes of different chemotherapy regimens in OS treatment.
• Further analysis of the specific protocols and their comparative efficacy is warranted.